இந்தியன் மருந்து சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இந்தியன் மருந்து சந்தை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இந்தியன் மருந்து சந்தை Today - Breaking & Trending Today

Eris Lifesciences Q4 PAT up 21% YoY on strong show by superspecialty biz


Riding on some of its top brands in the chronic superspecialty segment, formulations manufacturing company Eris Lifesciences Ltd has posted a 21 per cent growth in its consolidated profit after tax (PAT) at Rs 68.25 crore for the quarter ended March 31, 2021.
The company had posted a PAT of Rs 56.27 crore for Q4 of previous fiscal 2019-20. Eris consolidated total income for the fourth quarter of FY 2020-21 grew by 13 per cent to stand at Rs 280.42 crore, up from Rs 247.5 crore of the corresponding quarter last year.
In a year full of multiple disruptions, Eris Lifesciences clocked a 15 per cent growth in MR productivity and grew by 6.2 per cent year-on-year (YoY) in FY21, outperforming by 2x the covered market which grew at 2.9 per cent YoY, making it the third consecutive year of Eris outperforming the covered market and the Indian Pharmaceutical Market (IPM). ....

Amit Bakshi , Eris Lifesciences Ltd , Eris Lifesciences , Indian Pharmaceutical Market , Executive Director , Chief Operating Officer , Managing Director , Healthcare Sector , Healthcare Firms , Healthcare Companies , Healthcare Stocks , Healthcare Startups , அமித் பக்ஷி , எரிஸ் ஆயுள் அறிவியல் லிமிடெட் , எரிஸ் ஆயுள் அறிவியல் , இந்தியன் மருந்து சந்தை , நிர்வாகி இயக்குனர் , தலைமை இயங்குகிறது அதிகாரி , நிர்வகித்தல் இயக்குனர் ,

A bitter pill: Domestic pharma market growth slides to 1.1% in February


Domestic pharma market is witnessing a slow recovery, with growth crawling to 1.1 per cent in February after a 4.5 per cent growth in the previous month. December, in fact, was a strong month the industry clocked an 8.5 per cent growth.
In February, the key therapy areas of the Indian Pharmaceutical Market (IPM) witnessed slow growth while cardiac grew 7.3 per cent compared to 8.8 per cent in the month before, anti-diabetic reported 4.3 per cent growth.
Sheetal Sapale, president, marketing for AIOCD AWACS, a market research firm, said as anti-infectives and respiratory therapies have failed to register growth, the overall IPM growth has been slow. ....

Sheetal Sapale , Indian Pharmaceutical Market , Pharma Sector , Indian Drug Makers , Drug Companies , Respiratory Therapies , இந்தியன் மருந்து சந்தை , பார்மா துறை , இந்தியன் மருந்து தயாரிப்பாளர்கள் , மருந்து நிறுவனங்கள் , சுவாச சிகிச்சைகள் , நுண்ணுயிர் எதிர்ப்பிகள் ,

Torrent Pharma Q3 net up by 18% to Rs 297 cr even as US revenues dip


Despite a 24 per cent hit on its US business, Ahmedabad-based Torrent Pharmaceuticals Ltd (TPL) registered an over 18 per cent growth in its consolidated net profit for the third quarter ended December 31, 2020.
The company s consolidated net profit for the quarter was Rs 297 crore as against Rs 251 crore in the corresponding period last year.
Not only did Torrent Pharma s US revenues fall by 24 per cent to Rs 292 crore, its India revenues grew in single digits of seven per cent to stand at Rs 930 crore in the quarter. As a result, the company s consolidated total revenue from operations fell marginally by less than one per cent to close at Rs 2,003 crore in Q3 of FY 2020-21, as compared to Rs 2,019 crore in Q3 of FY 2019-20. ....

Torrent Pharmaceuticals Ltd , Ahmedabad Based Torrent Pharmaceuticals Ltd , Torrent Pharma , Indian Pharmaceutical Market , Torrent Pharma Results , Q3 Results , Pharma Sector , Pharma Sales , நீரோடை மருந்துகள் லிமிடெட் , அஹமதாபாத் அடிப்படையிலானது நீரோடை மருந்துகள் லிமிடெட் , நீரோடை பார்மா , இந்தியன் மருந்து சந்தை , நீரோடை பார்மா முடிவுகள் , குயிவ் 3 முடிவுகள் , பார்மா துறை , பார்மா விற்பனை ,

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%


Ahmedabad-based drug maker Eris Lifesciences Ltd. has posted a 42 per cent rise in its consolidated net profit for the third quarter of financial year 2020-21 at Rs 90.1 crore. Last year the company registered a consolidated Q3 net profit of Rs 63.4 crore.
The company s consolidated total income grew by 14 per cent to Rs 313.4 crore in the said quarter, as compared to Rs 274.8 crore in Q3 the previous fiscal.
Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients (VMN). Excluding Covid molecules, the company saw a year-on-year (YoY) growth of 15.6 per cent as against a five per cent growth by the Indian Pharmaceutical Market (IPM) in Q3 of FY 21. ....

Arvind Smartspaces , Eris Lifesciences Ltd , Eris Lifesciences , Excluding Covid , Indian Pharmaceutical Market , Eris Lifescience , எரிஸ் ஆயுள் அறிவியல் லிமிடெட் , எரிஸ் ஆயுள் அறிவியல் , இந்தியன் மருந்து சந்தை ,